nejm semaglutide heart failure New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis In the second episode of

Obesity itself significantly impairs testosterone production, and weight loss typically improves hormonal profiles rather than impairing them

5 The annual incidence ranges from 8.8 to 23.1 per 100,000 person-years in North America, 0.624.3 per 100,000 person-years in Europe, and 7.317.4 per 100,000 person-years in Oceania, with a prevalence in adults in their 30 s and 40 s

Dietary modifications play a crucial role in managing symptoms

Semaglutide and similar GLP-1 medications are not the same hormone but rather a chemical that mimics the same effects by triggering the same hormonal receptors in the same way

Its essential to have regular follow-up appointments with a clinician to monitor your progress and adjust the treatment as needed